Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + Sintilimab + S-1 versus Irinotecan Liposome + S-1 in second-line advanced pancreatic cancer
ChiCTR2500109834Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Sep 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised trial in pancreatic adenocarcinoma (PDAC) comparing Chidamide + Sintilimab + S-1 with Irinotecan liposome + S-1 (2 arms). Primary endpoint: progression-free survival. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
tucidinostatsintilimabtegafuririnotecan liposome
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR2500109834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109834.